153 related articles for article (PubMed ID: 36736527)
21. Sex differences in immune-related adverse events with immune checkpoint inhibitors: data mining of the FDA adverse event reporting system.
Chen C; Zhang C; Jin Z; Wu B; Xu T
Int J Clin Pharm; 2022 Jun; 44(3):689-697. PubMed ID: 35449347
[TBL] [Abstract][Full Text] [Related]
22. Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database.
Ma Z; Pei J; Sun X; Liu L; Lu W; Guo Q; Lyu J; Liu Y; Zhang Y; Zhao Z
Front Pharmacol; 2021; 12():663088. PubMed ID: 34276364
[No Abstract] [Full Text] [Related]
23. Comparison of pneumonitis risk between immunotherapy alone and in combination with chemotherapy: an observational, retrospective pharmacovigilance study.
Li H; Zheng Y; Xu P; Li Z; Kuang Y; Feng X; He J; Li J; Chen X; Bai L; Tang KJ
Front Pharmacol; 2023; 14():1142016. PubMed ID: 37124234
[No Abstract] [Full Text] [Related]
24. Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021.
Jiang T; Su H; Xu J; Li C; Zhang N; Li Y; Wu Y; Ni R; Ming Y; Li Z; Li L; Liu Y
Ther Adv Drug Saf; 2024; 15():20420986231224227. PubMed ID: 38293566
[TBL] [Abstract][Full Text] [Related]
25. Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: An analysis of FAERS data in the past 15 years.
Zhang P; Lao D; Chen H; Zhao B; Du Q; Zhai Q; Ye X; Yu B
Front Immunol; 2022; 13():778635. PubMed ID: 36081514
[TBL] [Abstract][Full Text] [Related]
26. Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system.
Yan YD; Zhao Y; Zhang C; Fu J; Su YJ; Cui XL; Ma EL; Liu BL; Gu ZC; Lin HW
EClinicalMedicine; 2022 Aug; 50():101535. PubMed ID: 35812997
[TBL] [Abstract][Full Text] [Related]
27. Arrhythmic events associated with immune checkpoint inhibitors therapy: A real-world study based on the Food and Drug Administration Adverse Event Reporting System database.
Liu Y; Chen Y; Zeng Z; Liu A
Cancer Med; 2023 Mar; 12(6):6637-6648. PubMed ID: 36426382
[TBL] [Abstract][Full Text] [Related]
28. Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer.
Yamagata A; Yokoyama T; Fukuda Y; Ishida T
Cancer Chemother Pharmacol; 2021 Feb; 87(2):251-258. PubMed ID: 33394102
[TBL] [Abstract][Full Text] [Related]
29. Severe cutaneous adverse reactions associated with immune checkpoint inhibitors therapy and anti-VEGF combination therapy: a real-world study of the FDA adverse event reporting system.
Li C; Li Z; Sun Q; Xiang Y; Liu A
Expert Opin Drug Saf; 2024 Jun; 23(6):777-784. PubMed ID: 37622438
[TBL] [Abstract][Full Text] [Related]
30. Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database.
Zhou C; Peng S; Lin A; Jiang A; Peng Y; Gu T; Liu Z; Cheng Q; Zhang J; Luo P
EClinicalMedicine; 2023 May; 59():101967. PubMed ID: 37131541
[TBL] [Abstract][Full Text] [Related]
31. Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers.
Shimoji K; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Iwamoto H; Fujitaka K; Hamada H; Takeno S; Hide M; Teishima J; Ohdan H; Hattori N
JAMA Netw Open; 2020 Nov; 3(11):e2022906. PubMed ID: 33180128
[TBL] [Abstract][Full Text] [Related]
32. Guillain-Barré syndrome in patients treated with immune checkpoint inhibitors.
Fan Q; Hu Y; Wang X; Zhao B
J Neurol; 2021 Jun; 268(6):2169-2174. PubMed ID: 33475824
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022.
Wang Y; Cui C; Deng L; Wang L; Ren X
Front Immunol; 2023; 14():1127128. PubMed ID: 37292205
[TBL] [Abstract][Full Text] [Related]
34. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
35. Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study.
Bai X; Chen X; Wu X; Huang Y; Zhuang Y; Chen Y; Feng C; Lin X
J Endocrinol Invest; 2020 Oct; 43(10):1473-1483. PubMed ID: 32239475
[TBL] [Abstract][Full Text] [Related]
36. Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy.
Kitahara Y; Inoue Y; Yasui H; Karayama M; Suzuki Y; Hozumi H; Furuhashi K; Enomoto N; Fujisawa T; Funai K; Honda T; Misawa K; Miyake H; Takeuchi H; Inui N; Suda T
Respir Res; 2024 Jan; 25(1):25. PubMed ID: 38200501
[TBL] [Abstract][Full Text] [Related]
37. Ileus in patients treated with immune checkpoint inhibitors: A retrospective, pharmacovigilance study using Food and Drug Administration Adverse Event Reporting System database.
Gao S; He Z; Zhu J; Liang D; Zhao W; Yang S; Jiang W; Qiu K; Yu X; Wu J
Pharmacoepidemiol Drug Saf; 2022 Nov; 31(11):1199-1205. PubMed ID: 35689298
[TBL] [Abstract][Full Text] [Related]
38. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
39. Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies-pharmacovigilance database analysis with real-world data validation.
Guo XJ; Cai XT; Rong ZX; Zhang YP; Wen YX; Bai X; Wang J; Fu QJ; Guo ZQ; Long LL; Ma SC; Tang XR; Liu L; Guan J; Dong ZY; Wu DH
BMC Med; 2023 Jan; 21(1):6. PubMed ID: 36600276
[TBL] [Abstract][Full Text] [Related]
40. The Effect of Concomitant Usage of Analgesics on Immune Checkpoint Inhibitor-related Interstitial Lung Disease.
Manabe T; Iwayama K; Chuma M; Tasaki Y; Matsumoto S
In Vivo; 2023; 37(3):1260-1265. PubMed ID: 37103090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
